CN104293730B - 多能干细胞体外定向分化为心肌细胞的方法 - Google Patents
多能干细胞体外定向分化为心肌细胞的方法 Download PDFInfo
- Publication number
- CN104293730B CN104293730B CN201410490078.6A CN201410490078A CN104293730B CN 104293730 B CN104293730 B CN 104293730B CN 201410490078 A CN201410490078 A CN 201410490078A CN 104293730 B CN104293730 B CN 104293730B
- Authority
- CN
- China
- Prior art keywords
- concentration
- cell
- stem cell
- cardiac muscle
- culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 89
- 210000004413 cardiac myocyte Anatomy 0.000 title claims abstract description 88
- 230000004069 differentiation Effects 0.000 title claims abstract description 57
- 238000000034 method Methods 0.000 title claims abstract description 36
- 210000004027 cell Anatomy 0.000 claims abstract description 72
- 239000001963 growth medium Substances 0.000 claims abstract description 46
- 239000002243 precursor Substances 0.000 claims abstract description 45
- 239000006160 differential media Substances 0.000 claims abstract description 33
- 230000007774 longterm Effects 0.000 claims abstract description 19
- 238000012423 maintenance Methods 0.000 claims abstract description 15
- 230000000763 evoking effect Effects 0.000 claims abstract description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 32
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 30
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 27
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 claims description 24
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 229960005070 ascorbic acid Drugs 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 15
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 12
- 235000010323 ascorbic acid Nutrition 0.000 claims description 11
- 239000011668 ascorbic acid Substances 0.000 claims description 11
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 claims description 9
- KLGQSVMIPOVQAX-UHFFFAOYSA-N XAV939 Chemical compound N=1C=2CCSCC=2C(O)=NC=1C1=CC=C(C(F)(F)F)C=C1 KLGQSVMIPOVQAX-UHFFFAOYSA-N 0.000 claims description 8
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims description 7
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 7
- 238000004113 cell culture Methods 0.000 claims description 5
- WRKPZSMRWPJJDH-UHFFFAOYSA-N N-(6-methyl-1,3-benzothiazol-2-yl)-2-[(4-oxo-3-phenyl-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)thio]acetamide Chemical compound S1C2=CC(C)=CC=C2N=C1NC(=O)CSC1=NC=2CCSC=2C(=O)N1C1=CC=CC=C1 WRKPZSMRWPJJDH-UHFFFAOYSA-N 0.000 claims description 4
- 230000001464 adherent effect Effects 0.000 claims description 4
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 4
- -1 NEAA Chemical compound 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 210000000107 myocyte Anatomy 0.000 claims 1
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 abstract description 6
- 238000012216 screening Methods 0.000 abstract description 6
- 238000004114 suspension culture Methods 0.000 abstract description 6
- 238000007877 drug screening Methods 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 238000011160 research Methods 0.000 abstract description 4
- 208000013875 Heart injury Diseases 0.000 abstract description 2
- 238000002659 cell therapy Methods 0.000 abstract description 2
- 230000009067 heart development Effects 0.000 abstract description 2
- 238000000746 purification Methods 0.000 abstract description 2
- 210000004165 myocardium Anatomy 0.000 description 29
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 9
- 229910052791 calcium Inorganic materials 0.000 description 9
- 239000011575 calcium Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 239000011324 bead Substances 0.000 description 8
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 235000000069 L-ascorbic acid Nutrition 0.000 description 5
- 239000002211 L-ascorbic acid Substances 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 5
- 239000012190 activator Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 3
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 3
- 229960001948 caffeine Drugs 0.000 description 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000002242 embryoid body Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000009256 replacement therapy Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 108010085895 Laminin Proteins 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000000889 atomisation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002837 heart atrium Anatomy 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 description 2
- 229960003712 propranolol Drugs 0.000 description 2
- 230000000541 pulsatile effect Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- LAQPKDLYOBZWBT-NYLDSJSYSA-N (2s,4s,5r,6r)-5-acetamido-2-{[(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1r,2r)-1,2,3-trihydrox Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 description 1
- GDSOZVZXVXTJMI-SNAWJCMRSA-N (e)-1-methylbut-1-ene-1,2,4-tricarboxylic acid Chemical compound OC(=O)C(/C)=C(C(O)=O)\CCC(O)=O GDSOZVZXVXTJMI-SNAWJCMRSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 102000010825 Actinin Human genes 0.000 description 1
- 108010063503 Actinin Proteins 0.000 description 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 1
- 102100027875 Homeobox protein Nkx-2.5 Human genes 0.000 description 1
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 1
- 101000632197 Homo sapiens Homeobox protein Nkx-2.5 Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091005975 Myofilaments Proteins 0.000 description 1
- 102000008730 Nestin Human genes 0.000 description 1
- 108010088225 Nestin Proteins 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 102100026893 Troponin T, cardiac muscle Human genes 0.000 description 1
- 101710165323 Troponin T, cardiac muscle Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000002371 cardiac agent Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940095990 inderal Drugs 0.000 description 1
- 230000000053 inderal effect Effects 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000005055 nestin Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (3)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410490078.6A CN104293730B (zh) | 2014-09-23 | 2014-09-23 | 多能干细胞体外定向分化为心肌细胞的方法 |
PCT/CN2015/089046 WO2016045495A1 (zh) | 2014-09-23 | 2015-09-07 | 多能干细胞体外定向分化为心肌细胞的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410490078.6A CN104293730B (zh) | 2014-09-23 | 2014-09-23 | 多能干细胞体外定向分化为心肌细胞的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104293730A CN104293730A (zh) | 2015-01-21 |
CN104293730B true CN104293730B (zh) | 2017-07-28 |
Family
ID=52313688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410490078.6A Active CN104293730B (zh) | 2014-09-23 | 2014-09-23 | 多能干细胞体外定向分化为心肌细胞的方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN104293730B (zh) |
WO (1) | WO2016045495A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108192857A (zh) * | 2018-04-18 | 2018-06-22 | 重庆斯德姆生物技术有限公司 | 一种HCM心肌细胞培养液诱导iPSCs定向心肌分化的方法 |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104293730B (zh) * | 2014-09-23 | 2017-07-28 | 云南中科灵长类生物医学重点实验室 | 多能干细胞体外定向分化为心肌细胞的方法 |
US10561687B2 (en) | 2015-02-17 | 2020-02-18 | University Health Network | Methods for making and using sinoatrial node-like pacemaker cardiomyocytes and ventricular-like cardiomyocytes |
CN107709545A (zh) * | 2015-04-22 | 2018-02-16 | 吉纳知识产权控股私人有限公司 | 从干细胞生成肌肉谱系细胞 |
CN106520684B (zh) * | 2016-11-23 | 2019-08-27 | 厦门大学 | 一种心肌细胞培养基 |
CN106867961A (zh) * | 2017-03-27 | 2017-06-20 | 广州润虹医药科技有限公司 | 一种诱导多能干细胞形成中胚层细胞的诱导培养基及诱导方法 |
CN109666630A (zh) * | 2017-10-17 | 2019-04-23 | 澳门大学 | 多能干细胞分化为间充质干细胞的方法及其培养基和应用 |
CN107937338B (zh) * | 2017-11-30 | 2021-08-03 | 中山大学 | 一种来自多能干细胞的中胚层谱系间充质干细胞及其制备方法 |
CN108913655B (zh) * | 2018-07-16 | 2022-07-15 | 浙江大学 | 基于多能干细胞技术建立“人源性”心肌肥大模型的方法 |
CN111187750B (zh) * | 2020-01-17 | 2022-08-16 | 复旦大学附属中山医院 | 生物胺诱导多功能干细胞向心肌细胞分化的方法与应用 |
CN112680410B (zh) * | 2021-01-19 | 2022-08-02 | 上海爱萨尔生物科技有限公司 | 诱导多能干细胞分化培养心脏成纤维细胞的方法及其培养液 |
CN112813023A (zh) * | 2021-02-26 | 2021-05-18 | 澳门大学 | 诱导干细胞往心肌细胞方向分化及心肌细胞传代与纯化的方法及药剂 |
CN113046318B (zh) * | 2021-04-13 | 2023-04-18 | 中国科学院深圳先进技术研究院 | 一种诱导多能干细胞向造血前体细胞分化的培养基以及方法 |
CN113249310B (zh) * | 2021-05-17 | 2022-10-11 | 湖北大学 | 一种拓展性多能干细胞诱导分化为心肌细胞的方法及应用 |
CN113337458A (zh) * | 2021-06-02 | 2021-09-03 | 呈诺再生医学科技(珠海横琴新区)有限公司 | 一种提高多能干细胞定向诱导心肌细胞产量及纯度的方法 |
CN114891729B (zh) * | 2022-04-15 | 2024-04-05 | 北京全式金生物技术股份有限公司 | 叶酸在促进人多能性干细胞向心肌细胞分化中的应用 |
CN116042516A (zh) * | 2023-02-22 | 2023-05-02 | 深圳市寰宇生物科技有限公司 | 一种从人诱导性多能干细胞分化的心肌细胞球及其制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102762718A (zh) * | 2009-10-13 | 2012-10-31 | 干细胞技术公司 | 用于分化干细胞的重量克分子渗透压浓度控制 |
CN103228782A (zh) * | 2010-06-13 | 2013-07-31 | 中国科学院生物物理研究所 | 由干细胞制备心肌细胞的方法和组合物及其用途 |
CN103627671A (zh) * | 2007-01-30 | 2014-03-12 | 佐治亚大学研究基金会 | 产生中内胚层细胞及多能游走细胞的方法与细胞群及用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201500918YA (en) * | 2012-08-07 | 2015-04-29 | Singapore Health Serv Pte Ltd | Method, combination and/or composition for inducing cardiomyocyte differentation |
WO2014078414A1 (en) * | 2012-11-13 | 2014-05-22 | Joseph Wu | Chemically defined production of cardiomyocytes from pluripotent stem cells |
CN104293730B (zh) * | 2014-09-23 | 2017-07-28 | 云南中科灵长类生物医学重点实验室 | 多能干细胞体外定向分化为心肌细胞的方法 |
-
2014
- 2014-09-23 CN CN201410490078.6A patent/CN104293730B/zh active Active
-
2015
- 2015-09-07 WO PCT/CN2015/089046 patent/WO2016045495A1/zh active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103627671A (zh) * | 2007-01-30 | 2014-03-12 | 佐治亚大学研究基金会 | 产生中内胚层细胞及多能游走细胞的方法与细胞群及用途 |
CN102762718A (zh) * | 2009-10-13 | 2012-10-31 | 干细胞技术公司 | 用于分化干细胞的重量克分子渗透压浓度控制 |
CN103228782A (zh) * | 2010-06-13 | 2013-07-31 | 中国科学院生物物理研究所 | 由干细胞制备心肌细胞的方法和组合物及其用途 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108192857A (zh) * | 2018-04-18 | 2018-06-22 | 重庆斯德姆生物技术有限公司 | 一种HCM心肌细胞培养液诱导iPSCs定向心肌分化的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN104293730A (zh) | 2015-01-21 |
WO2016045495A1 (zh) | 2016-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104293730B (zh) | 多能干细胞体外定向分化为心肌细胞的方法 | |
Hill et al. | Human embryonic stem cell− derived vascular progenitor cells capable of endothelial and smooth muscle cell function | |
Rajala et al. | Cardiac differentiation of pluripotent stem cells | |
Lewandowski et al. | Techniques for the induction of human pluripotent stem cell differentiation towards cardiomyocytes | |
CN103834613B (zh) | 制备多能心血管前体细胞及维持其心血管分化能力的方法 | |
EP2539437B1 (en) | SMOOTH MUSCLE-LIKE CELLS (SMLCs) DERIVED FROM HUMAN PLURIPOTENT STEM CELLS | |
CN106062182A (zh) | 用于制备睫状缘干细胞的方法 | |
WO2022110180A1 (en) | Generation of neural progenitor cells from embryonic stem cells or induced pluripotent stem cells | |
CN105200007B (zh) | 从胎盘胎儿面绒毛膜中提取亚全能干细胞的方法 | |
Dergilev et al. | Comparison of cardiac stem cell sheets detached by Versene solution and from thermoresponsive dishes reveals similar properties of constructs | |
CN105255826A (zh) | 人诱导多功能干细胞向睾丸间质细胞的诱导分化方法及其用途 | |
CN105861428A (zh) | 一种诱导成纤维细胞转分化为心肌细胞的诱导培养基及其应用 | |
CN105420193B (zh) | 分化培养基及其在制备神经干细胞中的用途 | |
CN101711890A (zh) | 一种用于研究胚胎干细胞发育分化的细胞外基质凝胶模型 | |
Zhu et al. | Cardiac organoids: a 3D technology for modeling heart development and disease | |
CN108949688A (zh) | 一种来自多能干细胞的神经嵴谱系周细胞及其诱导分化方法 | |
CN115851578A (zh) | 一种3d悬浮诱导持续扩增肝祖细胞类器官和/或肝细胞类器官的试剂盒及其应用 | |
US20240228967A9 (en) | Vascularized cardiac organoid with a chamber structure and its preparation method | |
CN110506109A (zh) | 细胞培养物的制造方法 | |
CN117535227A (zh) | 一种构建腔室化和血管化心脏类器官的方法及其应用 | |
CN110511904A (zh) | 高质量多能干细胞的培养基、培养方法及其应用 | |
CN105969733A (zh) | 诱导分化hPSCs为谷氨酰胺能神经元的方法 | |
CN105087473A (zh) | 人胚胎干细胞体外定向诱导分化为角化细胞的细胞外基质筛选方法 | |
Vallabhaneni et al. | Suspension culture on microcarriers and as aggregates enables expansion and differentiation of pluripotent stem cells (PSCs) | |
CN108998441A (zh) | 一种三维肿瘤球培养基添加剂、培养基以及三维肿瘤球培养方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230526 Address after: 650500 No. 727 Jingming South Road, Chenggong District, Kunming City, Yunnan Province Patentee after: Li Tianqing Address before: No. 1 Boda Road, Yuhua District, Chenggong New City, Kunming City, Yunnan Province, 650500 Patentee before: YUNNAN KEY LAB OF PRIMATE BIOMEDICINE RESEARCH |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230630 Address after: Room 9320, National Science and Technology Entrepreneurship Building, Kunming University of Science and Technology, No. 296, Xuefu Road, Kunming, Yunnan 650031 Patentee after: Kunming Yuanmeng Life Science Research Institute Co.,Ltd. Address before: 650500 No. 727 Jingming South Road, Chenggong District, Kunming City, Yunnan Province Patentee before: Li Tianqing |
|
TR01 | Transfer of patent right |